Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Uridine triacetate
Подписчиков: 0, рейтинг: 0
Clinical data | |
---|---|
Trade names | Vistogard, Xuriden |
Other names | vistonuridine |
AHFS/Drugs.com | Monograph |
MedlinePlus | a616020 |
License data | |
Routes of administration |
By mouth |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Metabolism | Pyrimidine catabolic pathway |
Onset of action | Tmax = 2–3 hours |
Elimination half-life | 2–2.5 hours |
Excretion | Kidney |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.021.710 |
Chemical and physical data | |
Formula | C15H18N2O9 |
Molar mass | 370.314 g·mol−1 |
3D model (JSmol) | |
| |
|
Uridine triacetate (INN), formerly known as vistonuridine, is an orally active tri-acetylated prodrug of uridine used:
- in the treatment of hereditary orotic aciduria (brand name Xuriden /ˈzʊərədɛn/ ZOOR-ə-den);
- to treat people following an overdose of chemotherapy drugs 5-fluorouracil (5-FU) or capecitabine regardless of the presence of symptoms, or who exhibit early-onset, severe or life-threatening toxicity affecting the cardiac or central nervous system, and/or early-onset, unusually severe adverse reactions (e.g., gastrointestinal toxicity and/or neutropenia) within 96 hours following the end of fluorouracil or capecitabine administration (brand name Vistogard).
Uridine triacetate was developed, manufactured and distributed by Wellstat Therapeutics. It was granted breakthrough therapy designation by the U.S. Food and Drug Administration (FDA) and approved for use in the United States in 2015.
External links
- "Uridine triacetate". Drug Information Portal. U.S. National Library of Medicine.